Bristol Myers Squibb (BMY) and MyoKardia (MYOK) $13.1bn acquisition information including expected completion date, offer price and contact details are displayed in the acquisition details table below. An invaluable buyout factsheet for traders and investors looking to trade the merger arbitrage spread.
This deal was successfully consummated on November 16, 2020
MyoKardia (NASDAQ: MYOK) Acquisition
Receive FREE instant access to constantly updated MYOK news related to the current acquisition. Simply register by entering your email address to receive weekly publication updates. For more proprietary Merger Arbitrage Limited content and analysis on this buyout, click MyoKardia (MYOK). Proprietary commentary can also be accessed by simply entering a ticker symbol into the search box such as “MYOK“, or clicking on a stock ticker in the tag cloud at the foot of this article.
Traders and shareholders can review similar acquisition details on current takeover stocks by first selecting “DEALS” from the main menu above, then “Current Cash Deals” or “Current Stock Deals“. For previous acquisitions, select either “Closed Deals” or “Failed Deals“. See our Spread Tracker News for mergers and acquisitions updates on the existing T20 Index portfolio constituents. Additionally, check out our customized M&A PR Newswire or Business Wire press release news feeds exclusively for Merger Arbitrage Limited.
MyoKardia (NASDAQ: MYOK) Acquisition - Merger News and Events
The major acquisition news updates & events of MyoKardia (MYOK) by Bristol Myers Squibb (BMY) are listed below. A comprehensive data source for
- Traders looking to familiarize themselves with the Bristol Myers Squibb (BMY) buyout of MyoKardia (MYOK) and trade the merger arbitrage spread
- Existing shareholders and investors wishing to stay abreast of the latest deal developments.
Following the acquisition news section, there is an in-depth company profile.
MyoKardia Company Profile
MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which is in Phase III clinical trial that is designed to reduce left ventricular contractility to alleviate the functional consequences and symptoms of obstructive hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression, as well as in Phase II clinical trial for non-obstructive HCM.
The company also develops MYK-491, an orally-administered small molecule, which is in Phase IIa clinical trial that is designed to restore normal cardiac muscle contractility in the diseased dilated cardiomyopathy (DCM) heart. Its preclinical programs include MYK-224, a HCM-targeting candidate that is designed to reduce excess cardiac contractility and enhance diastolic function; LUS-1, which is used to counteract a muscle abnormality that results in impaired relaxation of the left ventricle; and ACT-1 targeting genetic DCM due to sarcomeric mutations and impaired calcium regulation.
The company has a collaboration with 23andMe, Inc., a consumer genetics and research company; and a strategic collaboration and license agreement with Fulcrum Therapeutics, Inc. to discover, develop and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Myokardia, Inc. was founded in 2012 and is headquartered in South San Francisco, California.
